PamelaMunsterMD

Clinical Trials

• Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies Start of enrollment: 2004 Mar 01

  Completed

  Phase 1

• Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors Start of enrollment: 2009 Sep 13

  Completed

  Phase 1

• Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab Start of enrollment: 2010 Mar 01

  Completed

  Phase 2

• Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer Start of enrollment: 2008 Dec 10

  Terminated

  Phase 2

• Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors Start of enrollment: 2010 Jan 01

  Completed

  Phase 1

• Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Start of enrollment: 2010 Jul 20

  Completed

  Phase 1, Phase 2

• An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies Start of enrollment: 2011 Oct 01

  Completed

  Phase 2

• Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors Start of enrollment: 2012 Jun 25

  Active, not recruiting

  Phase 1

• Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies Start of enrollment: 2012 Mar 27

  Completed

  Phase 1, Phase 2

• A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2012 Nov 12

  Terminated

  Phase 1, Phase 2

• A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors Start of enrollment: 2013 Feb 01

  Completed

  Phase 1

• Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Start of enrollment: 2013 Oct 22

  Active, not recruiting

  Phase 1, Phase 2

• A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety Start of enrollment: 2014 Feb 01

  Completed

  Phase 1

• A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol) Start of enrollment: 2013 Nov 01

  Completed

  Phase 1

• Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Start of enrollment: 2014 Feb 01

  Completed

  Phase 1

• A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 Start of enrollment: 2015 Jul 16

  Completed

  Phase 1

• Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies Start of enrollment: 2016 Dec 01

  Terminated

  Phase 1

• 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets Start of enrollment: 2016 Apr 01

  Withdrawn

  Early Phase 1

• Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair Start of enrollment: 2018 Jan 12

  Completed

  Phase 1

• Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer Start of enrollment: 2021 Mar 11

  Terminated

  Phase 2

• Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer Start of enrollment: 2021 Mar 31

  Withdrawn

  Phase 1

• Join now to see all